Aydın Bünyamin, Özçelik Serhat, Kilit Türkan Paşalı, Eraslan Sertaç, Çelik Mehmet, Onbaşı Kevser
University of Health Sciences, Kütahya Evliya Çelebi Training and Research Hospital, Division of Endocrinology and Metabolism, Kütahya, Turkey.
University of Health Sciences, Kartal Dr. Lütfi Kırdar City Hospital, Department of Endocrinology and Metabolism, İstanbul, Turkey.
Prim Care Diabetes. 2022 Apr;16(2):312-317. doi: 10.1016/j.pcd.2022.01.002. Epub 2022 Jan 6.
Both diabetes mellitus (DM) and iron deficiency anemia (IDA) are prevalent in every area of the world, and so, the possibility of these two diseases co-existing is also very high. It is our belief that clinical results of any correlation between iron status of the body and glycosylated haemoglobin (HbA1c) would be beneficial to many patients, therefore in this study, the effect of IDA on HbA1c was investigated.
MATERIALS - METHODS: A total of 146 patients with DM and IDA were evaluated prospectively. While the patients were administered 270 mg/day of ferrous sulphate (80 mg elemental iron) orally for three months for the treatment of IDA, no interventions were made for the treatment of DM. Patient levels of hemoglobin (Hb), hematocrit, red blood cells (RBC), mean corpuscular volume (MCV), platelet, white blood cells (WBC), serum iron, serum iron binding capacity (SIBC), ferritin, fasting plasma glucose (FPG), HbA1c, body mass index (BMI), C-reactive protein (CRP) values were measured at baseline and at the third month of treatment with iron, and were compared.
The median age of our patients was 45 (40-50) and median duration of diabetes was 3 years (1,75-5). While the baseline median Hb was 10.4 (mg/dL) (9.5-11.1), MCV was 74 (fL) (70.8-77), ferritin was 4 (ug/L) (3-6) at three months, Hb was measured at 12.6 (mg/dL) (12.1-13.2), MCV was measured at 82 (fL) (80-86), ferritin was measured at 15 (ug/L) (9-21.2) and was significantly higher compared to baseline values (p < 0.001). The baseline median HBA1c of patients was 7.09 ± 0.51 (%) and three month HBA1c was 6.69 ± 0.53 (%), which was significantly lower than when comparing baseline values with values at third month (p < 0.001). Baseline and three month values for FPG were 118 (mg/dL) (108-132) and 116 (mg/dL) (106-125) respectively, and there was no significant difference (p:0.07). A 2.2 mg/dL (1.5-3.5) increase in median Hb level accompanied a 0.4 % (0.2-0.6) decrease in median HbA1c levels (Spearman rho = -0.362; p < 0.001).
Our study has shown conclusivly that IDA is related to increased HbA1c concentrations and HbA1c decreases significantly following treatment with iron. IDA should be considered before making any decisions regarding diagnosis or treatment according to HbA1c.
糖尿病(DM)和缺铁性贫血(IDA)在世界各个地区都很普遍,因此,这两种疾病同时存在的可能性也非常高。我们认为,身体铁状态与糖化血红蛋白(HbA1c)之间任何相关性的临床结果都将使许多患者受益,因此在本研究中,我们调查了IDA对HbA1c的影响。
前瞻性评估了总共146例患有DM和IDA的患者。在患者口服270毫克/天硫酸亚铁(80毫克元素铁)治疗IDA三个月期间,未对DM进行干预。在基线以及铁剂治疗的第三个月测量患者的血红蛋白(Hb)、血细胞比容、红细胞(RBC)、平均红细胞体积(MCV)、血小板、白细胞(WBC)、血清铁、血清铁结合能力(SIBC)、铁蛋白、空腹血糖(FPG)、HbA1c、体重指数(BMI)、C反应蛋白(CRP)值,并进行比较。
我们患者的中位年龄为45岁(40 - 50岁),糖尿病的中位病程为3年(1.75 - 5年)。基线时中位Hb为10.4(毫克/分升)(9.5 - 11.1),MCV为74(飞升)(70.8 - 77),三个月时铁蛋白为4(微克/升)(3 - 6),此时Hb测量值为12.6(毫克/分升)(12.1 - 13.2),MCV测量值为82(飞升)(80 - 86),铁蛋白测量值为15(微克/升)(9 - 21.2),与基线值相比显著更高(p < 0.001)。患者的基线中位HBA1c为7.09 ± 0.51(%),三个月时HBA1c为6.69 ± 0.53(%),与基线值和第三个月的值相比显著更低(p < 0.001)。FPG的基线值和三个月值分别为118(毫克/分升)(108 - 132)和116(毫克/分升)(106 - 125),无显著差异(p:0.07)。中位Hb水平增加2.2毫克/分升(1.5 - 3.5)伴随着中位HbA1c水平下降0.4%(0.2 - 0.6)(斯皮尔曼秩相关系数 = -0.362;p < 0.001)。
我们的研究确凿地表明,IDA与HbA1c浓度升高有关,铁剂治疗后HbA1c显著降低。在根据HbA1c做出任何诊断或治疗决策之前,应考虑IDA。